1st Annual European Neuroscience Innovation Forum

FOR BUSINESS DEVELOPMENT, LICENSING & INVESTMENT

3rd of March 2026|HILTON ZURICH AIRPORT HOTEL | SWITZERLAND

Sachs Associates would like to say that we have enjoyed hosting you in-person and virtually, and thank those who participated in our Sachs Spring Life Sciences Week, which incorporated the 1st Annual European Neuroscience Innovation Forum (#Sachs_ENIF) and the 19th Annual European Life Sciences CEO Forum (#Sachs_ELSF). A special thank you goes to the excellent line-up of sponsors, chairs, panellists, an exhibitor, and presenters who made such a broad and interesting programme possible and to those who participated in-person and during the virtual week.

The Life Sciences Week has proven highly successful, with over 500 participants from 27 countries registered and nearly 2300 in-person & online meetings completed.

Publicly available recordings of the sessions and presentations from the event will be uploaded to the SachsTV YouTube channel in April.

We are looking forward to welcoming you again to our future events!

CONTRIBUTING SPONSOR:

NRx Pharmaceuticals, Inc.

Presenting Companies Included:

Amporin Pharmaceuticals AG logo
Amyl Therapeutics SRL logo
Aprecia Pharmaceuticals logo
Bioxodes SA logo
Curlim logo
Elkedonia SAS logo
Evox Therapeutics Ltd. logo
Galimedix Therapeutics, Inc. logo
IAMA Therapeutics S.r.l. logo
Macomics Ltd. logo
Reconnect Labs AG logo
SpliceBio, S.L logo
Vandria SA logo

Confirmed Keynote Speakers Included:

Jonathan Javitt
CEO, NRx Pharmaceuticals, Inc.
Richard Porter
Chief Business & Scientific Officer, uniQure

Speakers and Chairs Included:

Anne Marije van Harten
Investment Director, Apollo Health Ventures
Bernd Nosse
BD&L Technologies & Emerging Areas, Boehringer Ingelheim International GmbH
Emma Mead
Chief Scientific Officer, Alzheimer's Research UK Oxford Drug Discovery Institute, University of Oxford
Fabrizio Calisti
Medical Director, Angelini Ventures S.p.A.
Garth Smith
VP, BD & Partnerships, Ontario Brain Institute
Ginger Johnson
SVP, Neuroscience Lead, Lumanity
Gregor Macdonald
VP, Head of BD & Licensing, Search & Assessment, H. Lundbeck A/S
Jenny Laird
VP, Search & Evaluation Neuroscience, Eli Lilly and Company
Olav Zilian
Medical Advisor, FluoSphera SA
Olga Krylova
Head S&E Europe, BD, Otsuka Pharmaceutical Co., Ltd.
Thierry Laugel
Managing Partner, Kurma Partners
Victoria English
Co-Founder & Editor, Evernow Publishing Ltd, publisher of MedNous
Yury Kukushkin
Investment Partner, Hevolution
Alexander Gebauer
Co-Founder & Executive Chairman, Galimedix Therapeutics, Inc.
Andrea Chicca
Co-Founder & CEO, Synendos Therapeutics AG
Antonio Mazzeo
BD/M&A Executive Director, Angelini Pharma S.p.A.
Camille Nicoleau
Director Search & Evaluation - Neurology & Rare Diseases, Servier
Dani Bach
Managing Partner, Limani Partners
Davor Kosanic
CEO, Reconnect Labs AG
Delphine Charvin
Co-Founder & CEO, Elkedonia SAS
Diana Saraceni
Co-Founder & General Partner, Panakès Partners SGR SpA
Gabrielle Åhlberg Hillert
Chief Medical Officer, BioArctic AB
Gil Beyen
CEO, Montis Biosciences
Ivo Staijen
Head, Public Equity, HBM Partners AG
Jessica Tomé-Garcia
Lead Scientific Program Manager, The Michael J. Fox Foundation for Parkinson's Research
Josep Prous
Co-Founder & Chief Scientific Officer, CONNECTA Therapeutics, S.L.
Jyothis George
Chief Medical Officer, NodThera, Inc.
Karen Wagner
Managing Partner, Ysios Capital
Kathy Xiang
VP Business & Corporate Development, Compass Pathways
Kirsten Scott
Clinical Lead, AC Immune
Klaus Dugi
CEO, Vandria SA
Laurent Richebourg
CEO, Curlim
Lynsey Bilsland
Managing Director, Parkinson's Research Ventures Ltd
Marc Dechamps
CEO, Bioxodes SA
Megan McGill
CEO, Brenig Therapeutics
Michael Salzmann
CEO, AL-S Pharma AG
Nicki Thompson
CEO, TRIMTECH Therapeutics
Per Lundin
Co-Founder & CEO, Evox Therapeutics Ltd.
Richard Munton
Senior Business Development Director, F. Hoffmann-La Roche
Richard Porter
Chief Business & Scientific Officer, uniQure
Sahil Kirpekar
Managing Partner, Lumina Life Sciences
Sara Secall
Partner, Inveready Asset Management
Torsten Madsen
CEO, IAMA Therapeutics S.r.l.
Willem Broekaert
Managing Partner, V-Bio Ventures BV